Semaglutide

tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu, also known as Somarutide, is a novel glucagon-like peptide-1 (GLP-1) receptor agonist with a unique side-chain structure that plays a pivotal role in its effectiveness. The side chain of Somarutide consists of a series of amino acids, with alanine being a key component. The structure of alanine contains a chiral center, existing in both left- and right-handed Chemicalbook configurations.

Somarutide utilizes advanced technology to ensure the presence of only one specific configuration of alanine, significantly enhancing the drug’s purity and therapeutic efficacy. Additionally, the side chain of Somarutide allows for various chemical modifications, which can alter its bioactivity and pharmacokinetic properties, providing greater flexibility in diabetes treatment.

As a novel therapeutic agent for diabetes, Somarutide has been widely used in clinical practice. Beyond its role in managing blood glucose levels, it also aids in weight loss and reduces cardiovascular risk, offering additional health benefits to diabetes patients.

CAS No: 1118767-16-0

>>Download COA

Application:

• Diabetes Treatment: Enhances blood glucose control and insulin sensitivity.
• Weight Loss: Supports weight management and fat reduction.
• Cardiovascular Health: Lowers cardiovascular risk factors associated with diabetes.
• Drug Development: Serves as a platform for the creation of other GLP-1 receptor agonists and diabetes therapies.

Storage condition: Store in a cool, dry place, away from direct sunlight. Recommended storage temperature: -20°C.

Packing: Customized